Workflow
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
Celldex TherapeuticsCelldex Therapeutics(US:CLDX) ZACKSยท2025-08-07 22:56

Company Performance - Celldex Therapeutics reported a quarterly loss of $0.85 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.86, but worse than a loss of $0.54 per share a year ago, indicating a year-over-year decline [1] - The company posted revenues of $0.73 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 56.18%, and down from $2.5 million in the same quarter last year [2] - Over the last four quarters, Celldex has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Stock Performance - Celldex shares have declined approximately 15.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for Celldex is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.90 on revenues of $1.63 million, and for the current fiscal year, it is -$3.48 on revenues of $3.7 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Celldex operates, is currently in the top 41% of over 250 Zacks industries, indicating a favorable environment for potential stock performance [8]